Cargando…

Hypoxic isolated abdominal perfusion breaks through chemoresistance in recurrent FIGO stage IIIC and IV ovarian cancer

To overcome drug resistance in relapsed ovarian cancer, an isolated perfusion system was used to generate a higher local exposure to cytostatic drugs. In addition to cisplatin as the cytostatic agent of choice, the present study combined adriamycin and mitomycin in a three drugs regime due to their...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aigner, Karl R., Gailhofer, Sabine, Aigner, Kornelia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108027/ https://www.ncbi.nlm.nih.gov/pubmed/33981433 http://dx.doi.org/10.3892/mco.2021.2291

Ejemplares similares

Hypoxic Isolated Abdominal Perfusion (HAP) chemotherapy for non-operable advanced staged ovarian cancer with peritoneal carcinosis: an experience in 45 platinum-refractory ovarian cancer patients
por: Aigner, Karl Reinhard, et al.
Publicado: (2019)

Intra-arterial infusion chemotherapy versus isolated upper abdominal perfusion for advanced pancreatic cancer: a retrospective cohort study on 454 patients
por: Aigner, Karl R., et al.
Publicado: (2019)

Tumor response and the quality of life after isolated hypoxic pelvic perfusion for advanced G3 cervical cancer: A case series
por: Aigner, Karl R., et al.
Publicado: (2020)

Carotid artery infusion via implantable catheters for squamous cell carcinoma of the tonsils
por: Aigner, Karl Reinhard, et al.
Publicado: (2018)

Isolated thoracic perfusion with chemofiltration for progressive malignant pleural mesothelioma
por: Aigner, Karl Reinhard, et al.
Publicado: (2017)

Therapeutic Effect of Regional Chemotherapy in Diffuse Metastatic Cholangiocarcinoma
por: Vashist, Yogesh, et al.
Publicado: (2022)

Regional Chemotherapy Is a Valuable Second-Line Approach in Metastatic Esophageal Cancer after Failure to First-Line Palliative Treatment
por: Vashist, Yogesh, et al.
Publicado: (2022)

Efficacy of Regional Chemotherapy Approach in Peritoneal Metastatic Gastric Cancer
por: Aigner, Kornelia, et al.
Publicado: (2021)

Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer
por: Rutten, Marianne J., et al.
Publicado: (2015)

Approaching 10 years disease-free survival after isolated thoracic perfusion for advanced stage IV tonsil carcinoma: A case report
por: Aigner, Karl R., et al.
Publicado: (2020)

Case report: Extended Isolated Stopflow Limb Infusion (EISLI) for highly malignant osteosarcoma - complete pathological tumor remission and implantation of a knee joint prosthesis
por: Aigner, Kornelia, et al.
Publicado: (2023)

Parametrial involvement and decreased survival of women with FIGO stage IIIC1 cervical cancer
por: Chang, Hong, et al.
Publicado: (2023)

Treatment of FIGO 2018 stage IIIC cervical cancer with different local tumor factors
por: Ye, Yanna, et al.
Publicado: (2023)

Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc
por: Kuhn, W, et al.
Publicado: (1999)

Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer
por: Huang, Chen-Yu, et al.
Publicado: (2020)

Treatment Strategies and Prognostic Factors of 2018 FIGO Stage IIIC Cervical Cancer: A Review
por: Qin, Fengying, et al.
Publicado: (2022)

Validation of the 2018 FIGO Staging System for Predicting the Prognosis of Patients With Stage IIIC Cervical Cancer
por: Long, Xingtao, et al.
Publicado: (2023)

A Risk Stratification for Patients with Cervical Cancer in Stage IIIC1 of the 2018 FIGO Staging System
por: Liu, Xiaoliang, et al.
Publicado: (2020)

Discussion on the rationality of FIGO 2018 stage IIIC for cervical cancer with oncological outcomes: a cohort study
por: Li, Zhiqiang, et al.
Publicado: (2022)

A Suggested Modification to FIGO Stage IV Epithelial Ovarian Cancer
por: Métairie, Marie, et al.
Publicado: (2023)

Image-guided intensity-modulated radiotherapy in patients with FIGO IIIC1 cervical cancer: efficacy, toxicity and prognosis
por: Meng, Qingyu, et al.
Publicado: (2023)

Rationality of FIGO 2018 IIIC restaging of cervical cancer according to local tumor size: A cohort study
por: Duan, Hui, et al.
Publicado: (2023)

Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer
por: Luo, Yanlin, et al.
Publicado: (2016)

Pretreatment [(18)F]FDG PET/CT Prognostic Factors in Patients with Squamous Cell Cervical Carcinoma FIGO IIIC1
por: Burchardt, Ewa, et al.
Publicado: (2021)

Comparison of Postoperative Adjuvant Chemotherapy and Concurrent Chemoradiotherapy for FIGO2018 Stage IIIC1 Cervical Cancer: A Retrospective Study
por: Kagabu, Masahiro, et al.
Publicado: (2021)

Initial treatment for FIGO 2018 stage IIIC cervical cancer based on histological type: A 14‐year multicenter study
por: Ye, Yanna, et al.
Publicado: (2023)

Short-term intra-arterial infusion chemotherapy for head and neck cancer patients maintaining quality of life
por: Aigner, Karl R., et al.
Publicado: (2018)

Predicting tumor response and outcome of second-look surgery with (18)F-FDG PET/CT: insights from the GINECO CHIVA phase II trial of neoadjuvant chemotherapy plus nintedanib in stage IIIc-IV FIGO ovarian cancer
por: Aide, Nicolas, et al.
Publicado: (2020)

Tozzi classification of diaphragmatic surgery in patients with stage IIIC–IV ovarian cancer based on surgical findings and complexity
por: Tozzi, Roberto, et al.
Publicado: (2019)

A comprehensive analysis of the factors of positive pelvic lymph nodes on survival of cervical cancer patients with 2018 FIGO stage IIIC1p
por: Yan, Ding-Ding, et al.
Publicado: (2019)

Radical surgery versus standard surgery for primary cytoreduction of bulky stage IIIC and IV ovarian cancer: an observational study
por: Ren, Yulan, et al.
Publicado: (2015)

Feasibility of laparoscopic diaphragmatic peritonectomy during Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer
por: Tozzi, Roberto, et al.
Publicado: (2020)

Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy
por: Blankenstein, Stephanie A., et al.
Publicado: (2020)

Clinical Outcome of a FIGO Stage IV Gestational Choriocarcinoma
por: Milenković, Vera, et al.
Publicado: (2013)

FIGO staging in ovarian carcinoma and histological subtypes
por: Kehoe, Sean
Publicado: (2020)

Cost-effectiveness of primary debulking surgery when compared to neoadjuvant chemotherapy in the management of stage IIIC and IV epithelial ovarian cancer
por: Forde, Gareth K, et al.
Publicado: (2016)

A meta-analysis: neoadjuvant chemotherapy versus primary surgery in ovarian carcinoma FIGO stageIII and IV
por: Dai-yuan, Ma, et al.
Publicado: (2013)

Prerequisites to improve surgical cytoreduction in FIGO stage III/IV epithelial ovarian cancer and subsequent clinical ramifications
por: de Jong, Diederick, et al.
Publicado: (2023)

Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer
por: Xu, Xia, et al.
Publicado: (2016)

Survival analysis of revised 2013 FIGO staging classification of epithelial ovarian cancer and comparison with previous FIGO staging classification
por: Paik, E Sun, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fd2cc1vgl25l9k0ntrqehqiq92